Mesoblast Limited vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Mesoblast Limited trades at $16.96 (market cap $2.21B), while YieldMax NVDA Option Income Strategy ETF trades at $12.87. The key difference: Mesoblast Limited is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| MESO | NVDY | |
|---|---|---|
Market Cap | $2.21B | — |
Sector | Technology | Income / Options Overlay |
52-Week High | $20.96 | $17.96 |
52-Week Low | $12.88 | $11.58 |
Enterprise Value | $2.21B | — |
Trailing returns across standard periods
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →